Unlocking Value: 10 Stocks to Watch Now!
Value Radar: 10 Fresh Ideas + Full Valuation Deep‑Dive on Bristol Myers Squibb (BMY)
Date: January 15, 2026 (United States)
Market backdrop: The 10‑year U.S. Treasury yield sits around 4.15%–4.19% this week, a useful anchor for discount rates in equity valuation. (federalreserve.gov)
1) 10 Value‑Based Candidates To Research Now
What “value” means here: durable cash flows, reasonable leverage, and shares trading below a conservative appraisal of intrinsic value, with identifiable catalysts over the next 12–24 months.
- Bristol Myers Squibb (BMY) — pipeline‑led transition through loss‑of‑exclusivity; fresh assets (e.g., Cobenfy/KarXT) and lifecycle work on Opdivo; 2025 non‑GAAP EPS guidance raised to $6.70–$7.00. Deep‑dive below. (investors.bms.com)
- FedEx (FDX) — cost‑takeout delivering; DRIVE savings achieved in FY25; raised FY26 outlook; Freight spin‑off targeted June 1, 2026. (investors.fedex.com)
- State Street (STT) — fee engine with improving operating leverage; Q3‑25 EPS +23% y/y, strong capital ratios. (nasdaq.com)
- Nucor (NUE) — tariff‑aided steel pricing, mills segment strength; cyclical but disciplined capex. (reuters.com)
- Gilead (GILD) — resilient HIV franchise; 2025 product‑sales outlook raised; dividend discipline. (reuters.com)
- Amgen (AMGN) — Horizon integration, manufacturing expansion; diverse biologics pipeline. (amgen.com)
- Keurig Dr Pepper (KDP) — steady mid‑/high‑single‑digit algorithm; 2025 outlook raised; strategic coffee M&A optionality. (keurigdrpepper.com)
- Lowe’s (LOW) — cash‑return flywheel and share shrink; leverage to repair/remodel normalization (monitor housing). [Company IR/press.]
- Cummins (CMI) — dependable mid‑cycle cash flows; energy transition optionality via Accelera. [Company IR/press.]
- WestRock/Smurfit WestRock (post‑deal) — scale, synergy, and box demand normalization tailwinds. (ir.westrock.com)
2) Deep Dive: Bristol Myers Squibb (BMY) — Transitioning Through the Cliff
2.1 What BMY is today
- Business mix: oncology/immunology/hematology mainstays (Opdivo, Eliquis alliance with Pfizer), plus newer assets from acquisitions (Karuna/KarXT; Mirati; RayzeBio). 2024 revenue was $48.3B; operating cash flow $15.2B; year‑end cash $10.3B vs. total debt $49.4B (principal). (sec.gov)
- 2025 guide (most recent company update): revenue raised to ~$45.8–$46.8B in April 2025 and further to $47.5–$48.0B after Q3‑25; non‑GAAP EPS raised to $6.70–$7.00. (investors.bms.com)
- Cost actions: total program expanded to $3.5B savings through 2027. (reuters.com)
Key recent developments we will model around:
- Eliquis U.S. “maximum fair price” under IRA for Medicare starting in 2026, and U.S. generic entry expected April 1, 2028 per court‑upheld patents. EU LOE in 2H26 in key markets. (bms.com)
- Opdivo lifecycle: subcutaneous Opdivo Qvantig approved in Dec‑2024, an important share‑defense tool as core IV patents roll off later this decade; priority‑review sBLA for Hodgkin lymphoma has an April 8, 2026 PDUFA. (reuters.com)
- Karuna (KarXT; marketed as Cobenfy for schizophrenia in 2025): acquisition closed March 2024; launch in progress and part of “growth portfolio” momentum. (businesswire.com)
Why it screens as value now
- Shares price in prolonged LOE fear and leverage from 2024‑era dealmaking, leaving BMY on a single‑digit forward P/E versus large‑cap pharma peers in the teens. The company’s own guidance and cash generation anchor downside provided execution on the growth portfolio continues. (investors.bms.com)
2.2 Roadmap, end‑market context, and what’s changing
- Legacy pressure vs. growth offset
• Management flagged 2025 legacy portfolio revenue declines (Revlimid, Pomalyst, Sprycel, Abraxane), partly offset by growth brands; that pattern largely played out through 2025 with reiterated and then raised full‑year guidance. (news.bms.com)
• Eliquis: Medicare price cuts begin 2026; EU generics in 2H26; U.S. generics in 2028 per litigation outcomes—this is the single biggest near‑term swing factor. (bms.com) - Opdivo defense and expansion
• The subcutaneous formulation (Opdivo Qvantig) meaningfully reduces chair time and can slow erosion as biosimilar risks approach later this decade. Additional first‑line indications (e.g., cHL) are under priority review. (reuters.com) - New launch engine
• Cobenfy (KarXT) launched; multiple label expansions are in development, but management still has to prove durable uptake beyond early demand. (sec.gov)
3) Ground‑Up Valuation: FCFF DCF + Comparable Checks
We build a conservative, cross‑checked FCFF model from company‑reported baselines, layering in the IRA and LOE timing.
3.1 Core inputs (with corroboration)
- Starting financials (base year = 2024 actuals)
• Revenue $48.3B; operating cash flow $15.2B; capex ~$1.25B; cash $10.3B; total debt (principal) ~$48.9B; net debt ≈ $38.5B. (sec.gov) - 2025 revenue/EPS “frame” for near‑term normalization
• Latest 2025 guide (after Q3‑25): revenue $47.5–$48.0B; non‑GAAP EPS $6.40–$6.60 (earlier), then raised to $6.70–$7.00 by April update; we anchor to the higher EPS band as the latest management view into 2026. (tipranks.com) - Eliquis trajectory assumptions (explicit)
• 2026–2027 U.S. Medicare “maximum fair price” lowers the Medicare unit value; company’s investor statement frames 2026–2027 Eliquis revenue ranges of $10.5–$12.5B WW in 2026 and $8.5–$11.0B in 2027; U.S. generics from Apr 1, 2028. We embed a down‑shift in 2026–2027 and a larger step‑down in 2028. (bms.com) - Opdivo and growth portfolio
• Assume mid‑single‑digit growth for Opdivo through 2027 aided by Qvantig and new indications, tapering thereafter; growth portfolio (Reblozyl, Camzyos, Breyanzi, Cobenfy, etc.) supports total company stability into 2027. (Anchored by 2025 “growth portfolio” updates.) (barrons.com) - Margins and taxes
• 2025 gross margin guide ~72%; operating expenses ~$16B; tax rate ~18%. We model a non‑GAAP operating margin in the mid‑30s, reflecting historical profitability adjusted for higher amortization/deal costs on GAAP. (news.bms.com) - Capex and working capital
• Capex held at ~$1.3–1.5B; working‑capital changes net to modest over the cycle (consistent with 2024 cash‑flow cadence). (sec.gov) - Discount rate (WACC)
• Risk‑free set to the 10‑yr at ~4.15%–4.19% (Jan 2026). Large‑cap pharma beta historically ~0.6–0.7; equity risk premium 5.0%; after‑tax cost of debt ~4.5–5.0% given BMY’s mix. We use WACC = 8.0% (base), 7.0% (bull), 9.0% (bear). (federalreserve.gov)
3.2 FCFF path (explicit years 2026–2030; $ billions)
Method: FCFF anchored to cash generation (CFO – capex, adjusted for one‑offs) and cross‑checked vs. revenue/margin logic above.
Base case FCFF:
• 2026: 12.5 (IRA drag on Eliquis; growth brands offset)
• 2027: 12.7 (growth brands + Opdivo mix)
• 2028: 11.0 (U.S. Eliquis generics from Apr 1)
• 2029: 12.0 (growth assets scale)
• 2030: 12.8 (further ramp/efficiency)
Terminal growth g = 1.5% (mature pharma). Discount at 8.0%.Present value math (summarized)
• PV of 2026–2030 FCFF ≈ $48.7B; PV of terminal value ≈ $136.1B → Enterprise value ≈ $184.8B.
• Less net debt ≈ $38.5B (12/31/2024), equity value ≈ $146B. With ~2.04B diluted shares, intrinsic ≈ $72/share.Sensitivities
• Bear (WACC 9%, g 1%; deeper 2028 step‑down): $46/share.
• Base (as above): ~$72/share.
• Bull (WACC 7%, g 2%; stronger growth portfolio and Opdivo/cHL win flow‑through): ~$115/share.
Why these levels are reasonable: the explicit drop in 2028 is tied directly to the company’s own LOE/IRA disclosures, while the recovery assumes continued execution in the “growth portfolio” where BMY’s quarterly prints have shown mid‑teens contribution and repeated guide raises during 2025. (bms.com)
3.3 Comparable checks (sanity)
- Forward P/E: Using BMY’s 2025 non‑GAAP EPS midpoint ($6.85) and a ~$45 stock price implies ~6.6x—well below many large‑cap pharma peers (e.g., ABBV ~16x; GILD roughly low‑teens on 2025 EPS). This is consistent with the market pricing a steep, prolonged LOE hole. (news.bms.com)
- Balance sheet: Net debt ≈ $38.5B (12/31/24) is meaningful but supported by ~$15B annual operating cash flow, giving flexibility for debt tenders and bolt‑ons. (sec.gov)
4) What the market may be missing
- Subcutaneous Opdivo is not a panacea but does improve patient/provider convenience; it can slow share erosion and support extensions as biosimilar risk approaches. (reuters.com)
- The company has repeatedly adjusted 2025 guidance upward as the “growth portfolio” contribution accelerates; that underpins our base‑case margin and FCFF resilience pre‑2028. (investors.bms.com)
- Eliquis revenue contours are unusually transparent (IRA MFP table + LOE dates). Models that still assume a cliff in 2026 for the U.S. likely over‑penalize near‑term cash flows. (bms.com)
5) Risks
- Execution on growth brands (Cobenfy, Reblozyl, Camzyos, Breyanzi) and continued Opdivo label wins; weaker uptake would compress our FCFF path. (barrons.com)
- Policy and pricing (IRA implementation details, further reforms). (bms.com)
- Litigation/LOE timing variance outside the U.S. for Eliquis; competitive PD‑1 dynamics in immuno‑oncology. (bms.com)
6) Bottom Line and Price Map
- Intrinsic value range (DCF): $46–$115 per share, Base ≈ $72.
- Investment view: For value investors, BMY offers an attractive, cash‑backed setup if you can tolerate 2028’s U.S. Eliquis step‑down. Accumulate on weakness below ~$55 with a three‑ to five‑year horizon, expect elevated volatility around 2026–2028 policy/patent milestones.
- What to watch next 2–4 quarters: growth‑portfolio quarterly cadence; Opdivo sBLA (cHL) by April 8, 2026; any new IRA implementation updates; capital‑structure moves (debt tenders/buybacks). (news.bms.com)
7) Valuation “Audit Trail” — Key Sources and Cross‑Checks
- 2024 Form 10‑K (financials, cash flow, debt, product disclosures). (sec.gov)
- 2024 results and initial 2025 guidance (72% GM, ~$16B opex, tax ~18%). (news.bms.com)
- Q1‑2025 guidance raise; latest revenue/EPS bands. (investors.bms.com)
- Q3‑2025 results and outlook update. (tipranks.com)
- Eliquis IRA “maximum fair price” table and U.S. LOE date (Apr 1, 2028); legal background. (bms.com)
- Opdivo Qvantig (subcutaneous) FDA approval; priority review for cHL combination. (reuters.com)
- Karuna acquisition close and integration into the portfolio. (businesswire.com)
- Risk‑free rate (H.15 daily). (federalreserve.gov)
8) One‑liners on today’s other nine ideas (sources)
- FedEx: FY25 DRIVE savings met; FY26 guide raised; spin‑off of FedEx Freight targeted for June 1, 2026. (investors.fedex.com)
- State Street: Q3‑25 EPS beat; fee growth strong; CET1 ~11.3%. (nasdaq.com)
- Nucor: Q1‑25 beat on mills strength; tariff backdrop supportive. (reuters.com)
- Gilead: raised 2025 outlook; HIV strength offsets other pressures. (reuters.com)
- Amgen: U.S. manufacturing expansion; Horizon integration watch‑item. (amgen.com)
- Keurig Dr Pepper: 2025 net‑sales outlook raised; steady EPS guide; potential coffee platform dealmaking. (keurigdrpepper.com)
- Lowe’s: capital‑returns compounding; monitor housing/DIY elasticity. [Company IR/press.]
- Cummins: durable engine cash flows; energy transition via Accelera. [Company IR/press.]
- WestRock/Smurfit WestRock: combination creates global packaging scale; synergy capture is key. (ir.westrock.com)
Disclaimer: This independent analysis is for educational purposes only and is not investment advice. Do your own research and consider your objectives and risk tolerance.